In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues.

中文翻译：

---

预测对选择性CDK4 / 6抑制反应的基因组生物标志物：难以捉摸的研究进展。

在本期《癌细胞》中，龚等人。已分析了560个细胞系对选择性CDK4 / 6抑制剂abemaciclib的敏感性，并将具有特定基因组“ D细胞周期蛋白激活特征（DCAF）”的癌症定义为特别脆弱。这些发现将有助于随着这种药物类型的发展继续进行患者选择。